nach oben

Current Hypertension Reports

Erschienen in:

01.08.2010

Antihypertensive Effects of Aspirin: What is the Evidence?

verfasst von: Leonelo E. Bautista, Lina M. Vera

Erschienen in: Current Hypertension Reports | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Nonsteroidal anti-inflammatory drugs are known to increase blood pressure and blunt the effect of antihypertensive drugs. Surprisingly, it has been suggested recently that aspirin lowers blood pressure and could be used for preventing hypertension. This review summarizes published data on the effects of aspirin on blood pressure. Trials suggesting that aspirin administered at bedtime lowers blood pressure are uncontrolled, unmasked, and potentially biased. They also conflict with cohort studies showing an 18% increase in the risk of hypertension among aspirin users. Fortunately, short-term use of aspirin does not seem to interfere with antihypertensive drugs. Regardless of its effect on blood pressure, low-dose aspirin effectively prevents cardiovascular events in patients with and without hypertension, but its benefits should be carefully weighed against a potential increase in the risk of adverse effects such as gastric bleeding and hemorrhagic stroke, as well as a small increase in the risk of hypertension.

Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232–235.PubMed

Dubois RN, Abramson SB, Crofford L, et al.: Cyclooxygenase in biology and disease. FASEB J 1998, 12:1063–1073.PubMed

Harris RC, Breyer MD: Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001, 281:F1–F11.PubMed

Ajani UA, Ford ES, Greenland KJ, et al.: Aspirin use among U.S. adults: behavioral risk factor surveillance system. Am J Prev Med 2006, 30:74–77.CrossRefPubMed

Pignone M, Anderson GK, Binns K, et al.: Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med 2007, 32:403–407.CrossRefPubMed

Berger JS, Roncaglioni MC, Avanzini F, et al.: Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006, 295:306–313.CrossRefPubMed

Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71–86.CrossRef

Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289–300.PubMed

Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153:477–484.CrossRefPubMed

10.

MacMahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765–774.CrossRefPubMed

11.

Dersimonian R, Kacker R: Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007, 28:105–114.CrossRefPubMed

12.

Hermida RC, Fernandez JR, Ayala DE, et al.: Time-dependent effects of ASA administration on blood pressure in healthy subjects. Chronobiologia 1994, 21:201–213.PubMed

13.

Hermida RC, Fernandez JR, Ayala DE, et al.: Influence of aspirin usage on blood pressure: dose and administration-time dependencies. Chronobiol Int 1997, 14:619–637.CrossRefPubMed

14.

Hermida RC, Ayala DE, Calvo C, Lopez JE: Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. J Am Coll Cardiol 2005, 46:975–983.CrossRefPubMed

15.

Hermida RC, Ayala DE, Calvo C, et al.: Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives. Hypertension 2005, 46:1060–1068.CrossRefPubMed

16.

• Hermida RC, Ayala DE, Mojon A, Fernandez JR: Ambulatory blood pressure control with bedtime aspirin administration in subjects with prehypertension. Am J Hypertens 2009, 22:896–903. A noncontrolled trial of the effect of aspirin administered at bedtime in patients with prehypertension.CrossRefPubMed

17.

Hermida RC, Ayala DE, Calvo C, et al.: Response: Aspirin administered at bedtime as opposed to upon wakening has an effect on ambulatory blood pressure: further evidence. Hypertension 2004, 43:e22–e23.CrossRef

18.

Parati G, Staessen JA: Hypertension drug trials based on ambulatory blood pressure monitoring: When is a double-blind controlled design needed? J Hypertens 2003, 21:1237–1239.CrossRefPubMed

19.

Gould BA, Mann S, Davies AB, et al.: Does placebo lower blood-pressure? Lancet 1981, 2(8260–8261):1377–1381.CrossRefPubMed

20.

Mancia G, Omboni S, Parati G, et al.: Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 1995, 8:311–315.CrossRefPubMed

21.

Staessen JA, Thijs L, Bieniaszewski L, et al.: Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action. Hypertension 1996, 27:414–420.PubMed

22.

Howe P, Phillips P, Saini R, Kassler-Taub K: The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens 1999, 21:1373–1396.CrossRefPubMed

23.

Hansson L, Hedner T, Dahlof B: Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992, 1:113–119.CrossRefPubMed

24.

Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J: Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 2003, 21:1291–1298.CrossRefPubMed

25.

Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762.CrossRefPubMed

26.

Mansoor GA, White WB: Contribution of ambulatory blood pressure monitoring to the design and analysis of antihypertensive therapy trials. J Cardiovasc Risk 1994, 1:136–142.PubMed

27.

• Parker RA: Studies should be controlled, randomized, and blinded. Clin Pharmacol Ther 2009, 85:461–463. A review of arguments in favor of the use of placebo control groups and masking of treatment in randomized clinical trials.CrossRefPubMed

28.

Chrischilles EA, Wallace RB: Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population. J Gerontol 1993, 48:M91–M96.PubMed

29.

Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999, 106:13S–24S.CrossRefPubMed

30.

Gainer JV, Morrow JD, Loveland A, et al.: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998, 339:1285–1292.CrossRefPubMed

31.

Magagna A, Abdel-Haq B, Favilla S, et al.: Hemodynamic and humoral effects of low-dose aspirin in treated and untreated essential hypertensive patients. Blood Press 1994, 3:236–241.CrossRefPubMed

32.

Avanzini F, Palumbo G, Alli C, et al.: Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP)–Hypertension study. Am J Hypertens 2000, 13:611–616.CrossRefPubMed

33.

Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA: Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens 1999, 12:784–789.CrossRefPubMed

34.

Smith SR, Coffman TM, Svetkey LP: Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril. J Am Soc Nephrol 1993, 4:1133–1139.PubMed

35.

Polónia J, Boaventura I, Gama G, et al.: Influence of non-steroidal anti-inflammatory drugs on renal function and 24 h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens 1995, 13:925–931.CrossRefPubMed

36.

Guazzi MD, Campodonico J, Celeste F, et al.: Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacol Ther 1998, 63:79–86.CrossRefPubMed

37.

Moore TJ, Crantz FR, Hollenberg NK, et al.: Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension 1981, 3:168–173.PubMed

38.

Tison P, Ulicna L, Jakubovska Z, et al.: Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension. Am J Hypertens 1994, 7:46S–49S.PubMed

39.

Fisman EZ, Grossman E, Motro M, Tenenbaum A: Clinical evidence of dose-dependent interaction between aspirin and angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002, 16:379–383.CrossRefPubMed

40.

Boger RH, Bode-Boger SM, Kramme P, et al.: Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low dose acetylsalicylic acid. Br J Clin Pharmacol 1996, 42:721–727.CrossRefPubMed

41.

Zanchetti A, Hansson L, Leonetti G, et al.: Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens 2002, 20:1015–1022.CrossRefPubMed

42.

Dubach UC, Rosner B, Sturmer T: An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987). N Engl J Med 1991, 324:155–160.PubMed

43.

Dedier J, Stampfer MJ, Hankinson SE, et al.: Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002, 40:604–608.CrossRefPubMed

44.

Forman JP, Stampfer MJ, Curhan GC: Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005, 46:500–507.CrossRefPubMed

45.

Curhan GC, Willett WC, Rosner B, Stampfer MJ: Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002, 162:2204–2208.CrossRefPubMed

46.

Kurth T, Hennekens CH, Sturmer T, et al.: Analgesic use and risk of subsequent hypertension in apparently healthy men. Arch Intern Med 2005, 165:1903–1909.CrossRefPubMed

47.

• Forman JP, Rimm EB, Curhan GC: Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007, 167:394–399. This cohort study showed an increase in the risk of developing hypertension in regular users of aspirin and discussed potential sources of bias in this and previous studies of this hypothesis.CrossRefPubMed

48.

Wang J, Mullins CD, Mamdani M, et al.: New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study. Ann Pharmacother 2007, 41:937–943.CrossRefPubMed

49.

Bautista LE, Lopez-Jaramillo P, Vera LM, et al.: Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001, 19:857–861.CrossRefPubMed

50.

Sesso HD, Buring JE, Rifai N, et al.: C-reactive protein and the risk of developing hypertension. JAMA 2003, 290:2945–2951.CrossRefPubMed

Titel: Antihypertensive Effects of Aspirin: What is the Evidence?
verfasst von: Leonelo E. Bautista
Lina M. Vera
Publikationsdatum: 01.08.2010
Verlag: Current Science Inc.
Erschienen in: Current Hypertension Reports / Ausgabe 4/2010
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-010-0115-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Systolic Pressure, Diastolic Pressure, or Pulse Pressure as a Cardiovascular Risk Factor in Renal Disease

Inflammation and Therapy for Hypertension

Polypill: Lights and Shadows

The Metabolic Syndrome: How Do We Get There?

Aldosterone in the Pathogenesis of Chronic Kidney Disease and Proteinuria